Viveve Medical Inc. (VIVE): Street Finally Waking Up

    0
    26

    BlackRock Fund Advisors recently announced the acquisition of new stake in Viveve Medical Inc. (NASDAQ:VIVE). The institutional investor has increased its shareholding in the Healthcare company by 3,842.34% to 0.26 million shares with purchase of 0.25 million shares. This fresh investment now brings its stake to 1.65% valued currently at $0.15 million. In addition, Jane Street Capital LLC raised its holdings by 55671.0 to 55671.0 shares. And UBS Securities LLC has lifted its position by 413.38% or 28705.0 shares – to 35649.0 shares.

    With over 2.06 million Viveve Medical Inc. (VIVE) shares trading Friday and a closing price of $0.61 on the day, the dollar volume was approximately $1.26 million. The shares have shown a positive weekly performance of 9.25% and its price on 08/28/20 lost nearly -6.38%. Currently, there are 15.73M common shares owned by the public and among those 15.73M shares have been available to trade.

    An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for VIVE have a consensus price objective of $1.85. The analysts have set the share’s price value over the next 12 months at a high of $1.85 and a low of $1.85 should the stock experience a downside. Incidentally, analysts’ outlook for the Viveve Medical Inc. stock is 1.00 for the next 12 months. But an upside of 67.03% will see the stock hit the forecast high price target while mean target price for the stock is $1.85.

    Insiders at the company have transacted a total of 22 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 4 of these insider trades were purchases, accounting for 131,600 shares. Insider sales of the common stock occurred on 18 occasions, with total insider shares sold totaling 237,684 shares.

    The top 3 mutual fund holders in Viveve Medical Inc. are Polar Capital Global Healthcare T, Vanguard Extended Market Index Fu, and USAA Extended Market Index Fund. Polar Capital Global Healthcare T owns 8914.0 shares of the company’s stock, all valued at over $5045.0. The company bought an additional 8914.0 shares recently to bring their total holdings to about 0.06% of the shares outstanding. USAA Extended Market Index Fund bought 845.0 shares to bring its total holdings to over 2360.0 shares at a value of $1336.0. USAA Extended Market Index Fund now owns shares totaling to 0.02% of the shares outstanding.

    Shares of Viveve Medical Inc. (NASDAQ: VIVE) opened at $0.6279, down -$0.02 from a prior closing price of $0.65. However, the script later closed the day at $0.61, down -6.38%. The company’s stock has a 5-day price change of 9.25% and -3.41% over the past three months. VIVE shares are trading -51.71% year to date (YTD), with the 12-month market performance down to -94.11% lower. It has a 12-month low price of $0.53 and touched a high of $11.90 over the same period. Currently, 2.06 million shares have been traded, compared to an average intraday trading volume of 5.48 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.73%, 2.54%, and -29.74% respectively.

    Institutional ownership of Viveve Medical Inc. (NASDAQ: VIVE) shares accounts for 2.70% of the company’s 15.73M shares outstanding. Mutual fund holders own 0.16%, while other institutional holders and individual stakeholders account for 2.35% and 0.13% respectively.

    It has a market capitalization of $10.19M and a beta (3y monthly) value of 0.51. The earnings-per-share (ttm) stands at -$19.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 30.09% over the week and 11.51% over the month.

    Analysts forecast that Viveve Medical Inc. (VIVE) will achieve an EPS of -$0.53 for the current quarter, -$0.49 for the next quarter and -$1 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.53 while analysts give the company a high EPS estimate of -$0.53. Comparatively, EPS for the current quarter was -$13.51 a year ago. Earnings per share for the fiscal year are expected to increase by 78.60%, and 58.50% over the next financial year.

    If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Viveve Medical Inc. (VIVE) as a “Strong Buy” at a consensus score of 1.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”

    Looking at the support for the VIVE, a number of firms have released research notes about the stock. Stifel stated their Hold rating for the stock in a research note on July 23, 2019, with the firm’s price target at $3-$1. Raymond James coverage for the Viveve Medical Inc. (VIVE) stock in a research note released on July 23, 2019 offered a Mkt Perform rating with a price target of. Maxim Group was of a view on July 23, 2019 that the stock is Hold, while Stifel gave the stock Buy rating on April 17, 2018, issuing a price target of $6. Northland Capital on their part issued Outperform rating on January 05, 2018.

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here